PR Newswire
Acquisition Will Further Expand Chromium’s Capabilities
PLEASANTON, Calif.
, Aug. 7, 2025 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to acquire Scale Biosciences, Inc., a leader in innovative and scalable single cell analysis. The acquisition provides 10x with key inventions and technologies that will advance innovation across the company’s Chromium platform. It also helps broaden access to single cell analysis by making it more powerful, affordable, and accessible to researchers worldwide.
Scale Biosciences was founded by a multidisciplinary team of scientists and technologists with expertise in next generation sequencing, genomics, and bioinformatics. Their unique work in combinatorial indexing and quantum barcoding represents a key advancement in scalable single cell analysis and is now poised to reach more scientists through 10x’s innovation roadmap. Scale’s scientific founders, all of whom are joining 10x as advisors, are: Professor Garry Nolan at Stanford University, Professors Jay Shendure and Cole Trapnell at University of Washington and Frank Steemers.
“At 10x, we’re relentlessly innovating to build a world where single cell analysis is routine, accessible, and scalable at levels previously unimaginable,” said Serge Saxonov, CEO of 10x Genomics. “This acquisition is a step towards that vision – reflecting our commitment to accelerating adoption of single cell technologies. By integrating Scale’s inventions with 10x’s global platform and innovation engine, we will broaden the capabilities and reach of existing and future products.”
By bringing Scale’s capabilities into 10x, the company ensures that Scale’s technology will reach more researchers, enable more scientific breakthroughs, and support 10x’s mission to advance human health. This acquisition will support an ambitious multi-year product roadmap for single cell innovation – one that aims to dramatically scale both the number of cells and samples that can be analyzed, while preserving the rich, high-quality multiomic data that researchers expect from 10x.
“These inventions were designed to make single cell analysis dramatically more scalable and accessible,” said Garry Nolan, PhD, co-founder of Scale Biosciences and Professor at Stanford University. “They have already advanced biological discovery, and with 10x’s innovation engine, that impact will only accelerate. This integration will help the research community generate the high-quality data needed to drive AI-powered breakthroughs in medicine.”
“We are incredibly proud of what we’ve built at Scale and its impact advancing biological understanding in single cell analysis. Our integration with 10x will accelerate the adoption of our technology, helping it reach new customers and transformative emerging applications,” said Giovanna Prout, President and CEO of Scale Biosciences. “We look forward to 10x building on our pioneering work and supporting a broader global customer base that will drive the next wave of biological discovery.”
10x will support current Scale customers with ongoing experiments, as well as initiatives such as the 100 Million Cell Challenge and the Billion Cells Project. In addition, key Scale products will remain on the market.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s acquisition of Scale Biosciences, Inc., integration activities, potential commercial reach, potential impacts of its products and services and potential products, applications and capabilities. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics’ expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s most recently-filed 10-Q and 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors: [email protected]
Media: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-acquire-scale-biosciences-302524711.html
SOURCE 10x Genomics, Inc.
